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EDITORIAL
Physical activity, nutritional status and systemic
inflammation in COPD
Pierantonio Laveneziana*,# and Paolo Palange",+ on behalf of the ERS Research Seminar Faculty1
T
he European Respiratory Society (ERS) Research Seminar
entitled ‘‘Physical activity, nutritional status and systemic
inflammation in COPD’’ and organised by the "Clinical
Physiology and Exercise" ERS scientific group 4.01, brought
together international experts to discuss several important
aspects of physical activity, nutritional status and inflammation
in chronic obstructive pulmonary disease (COPD) including
pathology and pathophysiology, measurement, and clinical and
therapeutic implications. A brief summary of the 2-day meeting
held in Florence, Italy on November 11th and 12th, 2011, with the
main conclusions and perspectives, is hereafter reported.
COPD is undoubtedly a disease associated with an abnormal
inflammatory reaction in the lung, but accumulating evidence
shows that it is also associated with systemic inflammation
[1–4], particularly during exacerbations of the disease [5] with
consequences for the cardiovascular system, metabolism and
skeletal muscles [6, 7]. The systemic consequences that may
be related to systemic inflammation include: cardiovascular
disease, obesity, hypertension, type 2 diabetes, depression,
deconditioning, malnutrition, atrophy and dysfunction of
skeletal muscles, physical inactivity, osteoporosis, and anae-
mia and bone marrow dysfunction [8–20]. In the last decade,
the relationship of comorbidities with systemic inflammation
in COPD has been extensively investigated. This is because
most of the COPD patients (.70%) that are seen in the clinic
present with one or more comorbid conditions [7]. The clinical
association between chronic respiratory diseases, obesity,
cardiovascular and metabolic diseases is not surprising con-
sidering the epidemic proportion of these diseases and the fact
that they share common risk factors such as ageing, smoking,
low levels of physical activity and a Western obesogenic diet.
What is less appreciated is that all these diseases independently
predict cardiovascular risk and that the association between
chronic respiratory, cardiovascular and metabolic diseases is
likely to go beyond a simple association of frequent diseases
[21]. In fact, the current evidence, albeit modest, points towards
a possible synergy between chronic respiratory, cardiovascu-
lar and metabolic diseases in such a way that, when combined,
they probably interact to promote: 1) a worsening of their
natural evolution, 2) impaired functional capacity, 3) worsen-
ing of dyspnoea, 4) reduced health-related quality of life, and
5) increased mortality [1]. Some authors have suggested the
term ‘‘complex chronic diseases’’ to depict this situation [1].
This may refer either to patients with multi-morbidities or to
the fact that most chronic diseases (e.g. COPD and diabetes) do
not reflect one phenotype but are complex diseases with
different phenotypes in different disease stages. The implica-
tion of this concept is that treating only one chronic disease in
isolation while neglecting to pay attention to other concomi-
tant chronic conditions is likely to lead to suboptimal health
benefits. Importantly, an unprecedented increase in the pre-
valence of ‘‘complex chronic diseases’’ is expected in the
upcoming years [1]. Figure 1 depicts the different levels of
impairment in COPD.
It is of course tempting to propose a unifying mechanism
that would contribute to the development of the comorbid
conditions associated with COPD. One such possible mechan-
ism is systemic inflammation which may occur from the ‘‘spill-
over’’ of pro-inflammatory mediators from the lung to the
systemic circulation [6]. However, the following considerations
that point against the systemic nature of COPD should be
acknowledged: 1) systemic inflammation is heterogeneously
distributed over COPD patients [22]; 2) its stability over longer
periods of time has not been investigated [23]; 3) whether
systemic inflammation, severity of COPD, comorbidities and
mortality are intimately interrelated is at present unclear [24];
and 4) some evidence would suggest that comorbidities seem
to be related to age rather than disease severity [24]. The
question is, to date, still unanswered.
Regardless of the COPD–systemic inflammatory related nature
of comorbidities, an intriguing issue is whether comorbidities
may be related to the response to rehabilitation [7, 25].
Recently, a retrospective cohort study examined this question.
The authors found that the Charlson index and the presence of
metabolic disease and heart disease, all reduced the likelihood
of a response to rehabilitation (odds ratios ranging from 0.57–
0.72) [7]. The negative effect of cardiovascular comorbidities on
the response to rehabilitation was confirmed in another study
[25]. By way of contrast, rehabilitation is expected to have a
beneficial effect on most of the comorbidities that are frequently
present in patients undergoing pulmonary rehabilitation [26].
The relationship is, at present, still debated.
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Limb muscle dysfunction is another major manifestation of
COPD [20]. Muscle dysfunction is characterised by muscle
strength loss and endurance impairment, the latter being
inversely related to increased peripheral muscle fatigue [27–
30]. These functional disorders are related to diverse patho-
physiological changes in the muscle, namely bioenergetic
alterations (poor oxidative capacity) [31], fibre type redistribu-
tion (shift from type I to type II fibres) [32, 33], altered capil-
larisation [33], oxidative stress [34–38] and muscle wasting
[38–41] affecting a subpopulation of COPD patients. The path-
ogenic mechanisms responsible for these pathophysiological
changes are multifactorial. Systemic inflammation and oxida-
tive/nitrosative stress have been described among these path-
ogenic mechanisms responsible for muscle dysfunction in
COPD [42, 43]. The presence of markers of local inflammation
at muscle level is less clear and yet a debatable issue [36, 44–48].
COPD is, thus, a disease of the lungs with extrapulmonary
manifestations, among which skeletal muscle dysfunction is an
independent prognosis factor and it is responsible, in part, for
exercise intolerance in these patients [28–30, 40, 41, 43]. Exercise
training is a strategy aimed at restoring exercise tolerance
through improving respiratory, cardiovascular, metabolic and
peripheral muscle function. Less clear is the ability of exercise
training to improve systemic inflammation in COPD patients.
We know that exercise can trigger an inflammatory response
and oxidative stress in patients with COPD [49–52]. Non-
injurious (moderate intensity and short duration) exercise
increases the level of circulating inflammatory cells and
cytokines, by stimulating interleukin (IL)-6, IL-10 and IL-1ra
but inhibiting tumour necrosis factor (TNF)-a [53–55]. These
cytokines mobilise energy substrates by regulating glucose
metabolism and may regulate muscle remodelling and also
attenuate or inhibit the inflammatory response (‘‘anti-inflam-
matory’’ effect). However, injurious (high intensity and long
duration) exercise triggers an initial inflammatory response by
stimulating the release of cytokines (IL-1b and TNF-a) that play
a role in the degradation of damaged muscle [53–55]. This is
followed by a later phase of regeneration and repair with release
of anti-inflammatory cytokines (IL-10, IL-1ra and TNF-R) which
modulate muscle remodelling in response to exercise-induced
damage. The corollary of this is that ‘‘non-injurious’’ exercise in
absolute terms for a healthy subject may be intense (‘‘injurious
exercise’’) in relative terms for a COPD patient [50]. Indeed, for
the same intensity of exercise, COPD patients present an
increased lactate production [56]. Even when injurious exercise
seems to activate regeneration in healthy people, COPD patients
may be susceptible to perpetuated muscle damage [57]. In fact,
the magnitude and duration of the injurious and repair phases
of the inflammatory response induced by muscle contraction are
influenced by individual characteristics [58, 59]. In COPD
patients, the effect of systemic inflammation, ageing, lack of
previous exposure to exercise (i.e. sedentarism) and exacerba-
tions can be all implicated in a differential inflammatory
response to muscle contraction. Older individuals have muscles
that are injured more easily after exercise [58–60]. However,
several studies report an abnormal inflammatory response to
exercise in patients with COPD in comparison to age-matched
control subjects [56, 57], pointing out that ageing is only a
potential contributory factor. Repetitive bouts of exercise
experienced by COPD patients may, therefore, be deleterious.
Exercise training fails to reverse systemic inflammation and
contributes to impair redox status at muscle level [42, 57, 61, 62].
This situation seems to be even more evident in a subpopulation
of COPD patients with muscle wasting and low body mass
index [36, 42, 56, 63]. These patients may experience a smaller
‘‘therapeutic range’’ or training safety zone for effective but
safer exercise prescription or benefit from additional pharma-
cological or physiological (e.g. nutrition) interventions.
Despite this, exercise training has been proven to be beneficial
in ,70% of COPD patients in terms of exercise tolerance and
quality of life, at least in part by improving peripheral muscle
function [52, 64, 65]. But what happens in the remaining 30% of
COPD patients who benefit less or not at all from pulmonary
rehabilitation/exercise training [66]? The first issue to consider
before concluding that some patients are non-responders to
pulmonary rehabilitation is the definition of a non-response.
This is not a trivial issue because some patients may improve
in certain aspects of their disease (e.g. quality of life or
symptoms) while not showing large improvements in other
aspects (e.g. exercise tolerance). There is evidence that patients
with COPD who undergo exercise training experience compar-
able small decreases in dyspnoea intensity, regardless of
whether or not they demonstrate improved exercise tolerance
[67]. Should we conclude that such a patient does not respond to
rehabilitation? Another issue to consider is the responsiveness
of the testing modalities that we use to quantify the impact of
pulmonary rehabilitation. For example, some patients may
show improvement in exercise tolerance on the constant work-
rate endurance cycling test and not on the 6-min walking test
[68]. It becomes obvious from these observations that caution
should be used before declaring that a patient does not benefit
from pulmonary rehabilitation. This being said, it has to be
acknowledged that the magnitude of response to pulmonary
rehabilitation in COPD is highly variable with some patients
showing little or no benefit at all. Similar observations have been
made in healthy individuals and there is a genetic component to
this phenomenon [69–71]. As such, the high individual
variability in the response to training is not unique to COPD.
It is also interesting to consider that the nature of the skeletal
muscle response to exercise training may differ in patients

























FIGURE 1. The different levels of impairment in chronic obstructive pulmonary
disease (COPD). FEV1: forced expiratory volume in 1 s.
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response to exercise training may also be related to the inability
to tolerate sufficient intensity and/or duration of training and/
or to poor compliance to the training intervention. For example,
high intensity or longer duration programmes have been
associated with a larger response compared with less intense
or shorter programmes [73, 74]. Patients who present with
significant contractile fatigue after an exercise training session
also show more pronounced training effects [75]. Some COPD
patients with pronounced muscle wasting (cachectic patients)
seem to be more prone to the effect of oxidative stress and
inflammation at the muscle level [51, 62, 63, 76]. This issue is
important because muscle wasting occurs in ,35% of severe
COPD patients eligible for pulmonary rehabilitation [77] but also
in 20% of outpatients with moderate airflow obstruction [78],
and is predictive of increased mortality [40, 41]. In addition, there
are studies indicating that several mechanisms impair muscle
remodelling in cachectic COPD patients, such as inhibition of
myogenesis, increased protein degradation and decreased
protein synthesis [76, 79]. Although exercise training/pulmon-
ary rehabilitation produces less peripheral muscle fibre pheno-
typical adaptations/remodelling in cachectic than in non-
cachectic COPD patients, cachectic COPD patients are able to
increase exercise capacity as much as those without cachexia
[80]. It is tempting to speculate that the limited training effect in
peripheral muscle fibre remodelling in cachectic COPD patients
could be attributed to the simultaneous activation of hypertro-
phy (insulin-like growth factor 1 and mechano-growth factor)
and atrophy (ubiquitin proteasome) signalling pathways with
exercise training [80]. However, this really needs to be confirmed
in future research. In addition, it should be emphasised that both
training intensity and duration may have also played a crucial
role in the blunted response to exercise training in cachectic
COPD.
It is clear that, from a clinical standpoint, predicting the
effectiveness and the magnitude of the response to exercise
training in an individual COPD patient remains challenging.
The initial mechanisms of exercise limitation appear to affect
the exercise outcome to pulmonary rehabilitation [81]. Recent
information suggests that COPD patients who develop quad-
riceps contractile fatigue during exercise training show greater
training effects in terms of functional exercise capacity and
health-related quality of life [75]. The typical clinical portrait of
a patient with COPD ‘‘responder’’ to exercise training looks
like someone whose poor exercise tolerance is related mainly
to weak skeletal muscles (i.e. fatigue) and not to ventilatory
limitation/constraint [66, 81]. The corollary of this is, therefore,
that ‘‘non-fatiguers’’ should benefit less from rehabilitation
than ‘‘fatiguers’’. This is, however, not completely true,
because it has recently been shown that exercise tolerance
has improved after rehabilitation even in ‘‘non-fatiguers’’ [75].
The picture is very complex, and may involve several other
contributing factors such as exertional dyspnoea, ventilatory
limitation/constraint, dynamic lung hyperinflation and lack of
motivation. Strategies are currently under investigation to
improve the rate of response to pulmonary rehabilitation. The
first step is to optimise the pharmacological treatment [82].
Oxygen [83], heliox [84], noninvasive ventilation [85], interval
training [86], one-legged exercises [87] and nutritional support
as adjunct to exercise training [88, 89] are examples of
pharmacological and non-pharmacological interventions.
Several unanswered questions need to be addressed in the
future: 1) the definition of non-responders from a research
standpoint and from a clinical standpoint; 2) it is still unclear
what happens in the peripheral muscles of non-cachectic
COPD patients (at least 40%) who do manifest a reduction of
the systemic inflammatory mediator levels or the local muscle
expression of TNF-a and IL-6 in response to exercise training;
3) the mechanisms by which exercise capacity improves after
rehabilitation in cachectic COPD patients in spite of less
peripheral muscle fibre phenotypical adaptations than non-
cachectic COPD patients, are still unknown and await a better
understanding of their underlying physiology; 4) the potential
role of ventilatory constraints and exertional dyspnoea in mo-
dulating the response to exercise training in cachectic COPD
patients is still unknown and needs to be explored; 5) exercise
training has been shown to reverse some of the metabolic
abnormalities associated with deconditioning and ameliorate
exercise tolerance; however, optimisation of training pro-
grammes is needed; 6) what is the best approach to intervene:
nutritional or anabolic supplements alone or in combination with
exercise; 7) nutritional supplements to be given: high content of
proteins (20% of total calories), or predominance of carbohy-
drates over fat, or antioxidants enrichment?; 8) the role of
anabolic agents, ghrelin (orexigenic properties), N-3 polyunsatu-
rated fatty acids and, recently, the involvement of peroxisome
proliferator-activated receptors; 9) in selected patients, such as
cachectic COPD patients, a promising approach is represented by
the integration of adequate increased caloric intake (until body
mass is recovered) with muscle training; and 10) the involvement
of other organs (e.g. adipose tissue) and (changes in) body
composition in systemic inflammation.
Nonetheless, even when taking into account the proportion
of non-responders, pulmonary rehabilitation remains a very
effective, safe and potent intervention to improve quality of
life, dyspnoea and exercise tolerance in COPD.
The complex interplay between dynamic hyperinflation, pul-
monary inflammation and acute exacerbation in COPD has
not been fully elucidated. The question arises as to whether
hyperinflation could contribute to the inflammatory conse-
quences of COPD and how, in turn, exacerbations could worsen
hyperinflation.
Hyperinflation, both occurring at rest (static hyperinflation)
and during exercise (dynamic hyperinflation), and exacerba-
tions are two critical features of COPD. Their presence
profoundly affect the clinical picture of the disease since they
are associated with dyspnoea [90], exercise intolerance [90],
negative energy, balance/weight loss, more rapid decline in
forced expiratory volume in 1 s [91, 92] and poor quality of life
[93]. As such, having a better understanding of the interplay
between these three features of COPD would seem important to
help to develop more efficient therapeutic interventions for this
disease. Hyperinflation and exacerbation may be considered to
be independent from each other: hyperinflation is typically
considered as a pure mechanical event while exacerbations
would be described as inflammatory phenomena, characterised
by a worsening in airway and systemic inflammation [94, 95].
Whether the mechanical derangements of the respiratory
system seen in COPD could contribute to the inflammatory
state has been discussed recently [96]. The most convincing
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evidence in support of this theory is emerging from the field of
critical care and acute respiratory distress syndrome, suggesting
that lung over-distention may be associated with the release
from the lungs of pro-inflammatory cytokines in the systemic
circulation [97]. Conversely, a mechanical ventilation strategy
that aims at minimising over-distention has been reported to
reduce the systemic pro-inflammatory cytokine response [98].
From these data, it is tempting to speculate that a similar
systemic inflammatory response may also be associated with the
occurrence of dynamic hyperinflation in COPD. There is,
however, only meagre evidence supporting evidence for this
concept. We know for example that exercise may be associated
with an increase in inflammatory markers in the systemic
circulation in patients with COPD, particularly in the presence
of cachexia [50, 51]. It is however uncertain whether this
immunological response originates from the distended lungs or
whether it comes from the contracting limb muscles and/or
from the activation of inflammatory cells. Along this line, it
should be noted that healthy subjects also exhibit an exercise-
related immunological response that is occurring despite the
fact that operating lung volumes remain stable or even decrease
during exercise in these individuals. This makes it difficult to
ascribe the immunological response seen in COPD solely to the
presence of dynamic hyperinflation.
The evidences regarding the potential impact of over-distention
on inflammation in COPD are only indirect and potentially
conflicting. Inhaled corticosteroids alone do not exert a huge
impact on airway inflammation associated with COPD [99] but
have been reported to be associated with a decrease in systemic
inflammation [100, 101] and, more recently, with lung deflating
effects [102]. This would seem to argue for a potential inflam-
matory effect of lung over-distention in COPD. Conversely, the
fact that obese patients with COPD breathe at lower lung
volumes compared with their lean counterparts [103] while
exhibiting a greater degree of systemic inflammation [104] does
not support the idea that hyperinflation is a major player in the
creation of a systemic inflammatory response in this disease. In
fact, obesity that is clearly associated with a reduction in lung
volumes is a strong predictor of the level of systemic inflamma-
tion seen in COPD.
The current evidence does not allow a definitive conclu-
sion to be drawn on the potential relationship between lung
over-distention and systemic inflammation in COPD. At the
same time, exacerbations which are most commonly seen as
inflammatory events are also associated with mechanical
derangements within the respiratory system, including worsen-
ing in hyperinflation [105, 106]. Considering that exacerbations
are currently defined based on dyspnoea worsening, these
mechanical derangements which modulate the perception of
dyspnoea are central in the definition and recognition of an
exacerbation. It can thus be envisioned as a vicious cycle where
exacerbations promote further worsening in lung over-disten-
tion which in turn might promote more inflammation and
worsening in pulmonary function [96].
The starting point for this research seminar was the well-
known physical inactivity in COPD that for many years has
been blamed on abnormal peripheral muscle function and
respiratory function, reflected by both lung mechanics and gas
exchange. The principal overarching question posed was
whether part of the blame lies with the systemic inflammation
as well, and if so, how.
Several lines of evidence do suggest that COPD is associated
with systemic inflammation which may lead to consequences
(comorbidities?) for the cardiovascular system, metabolism
and skeletal muscles. However, such evidence, coming from
morphological, biochemical and physiological measures that
have only recently begun to be studied in depth, is itself
somewhat difficult to interpret, so that while such comorbid-
ities clearly exist, whether they are related to a systemic
consequence of COPD per se (‘‘spill-over’’ of pro-inflammatory
mediators from the lung to the systemic circulation) or just to
ageing (patients with COPD are often elderly) or to clinical
COPD phenotypes independent of comorbid conditions,
remains at present unclear.
Part of the problem also resides in the fact that it is still not
entirely clear whether exercise has anti-inflammatory or pro-
inflammatory effects, and whether local and/or systemic inflam-
mation has deleterious effects on muscle contractility (fatiguers
versus non-fatiguers), whether it contributes to muscle wasting
(cachectic versus non-cachectic) and whether it has clinical
implication in the response to exercise training during a
rehabilitation programme in COPD (responders versus non-
responders). Part of the problem comes also from what
TABLE 1 Future research directions
Key points
Clarify the role of ageing, smoking, comorbidities and COPD phenotypes on systemic inflammation in COPD
Investigate the interplay between systemic inflammation, COPD severity, comorbidities and mortality in COPD
Investigate the interplay between systemic inflammation, skeletal muscle dysfunction and physical (in)activity in COPD
Rule out the deleterious effects of local and/or systemic inflammation on muscle contractility (fatiguers versus non-fatiguers), on muscle wasting (cachectic
versus non-cachectic) and on the clinical response to exercise training during a rehabilitation programme in COPD (responders versus non-responders)
Study an appropriate set of control subjects against which to compare exercise in patients with COPD and related comorbidities
Utilise an integrative approach that takes into account all potential systemic manifestations into a multidimensional picture for a proper evaluation of patients
with COPD
Focus on translational research using well phenotyped COPD patients with respect to disease severity and lifestyle factors
Investigate the potential interplay between dynamic hyperinflation, pulmonary inflammation and acute exacerbation in COPD
COPD: chronic obstructive pulmonary disease.
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constitutes the most appropriate exercise tests (cycling versus
walking) [107], modalities (incremental versus constant work
rate) [108], intensities and duration [108] as well as the most
appropriate set of control subjects against which to compare
exercise in patients with COPD and comorbidities.
The consensus of the group was that a proper evaluation of
patients with COPD requires an integrative approach that takes
into account all potential systemic manifestations into a multi-
dimensional picture. In this context, understanding the nature
and the extent of the interactions between chronic respiratory,
cardiovascular and metabolic diseases is an important medical
challenge of the 21st century, and failing to address this new
reality will only contribute to the progression of the phenom-
enon and to unparalleled adverse health consequences. In
conclusion, this workshop has laid out broad research directions
(table 1) to allow a better mechanistic understanding of the
relationship between physical (in)activity, nutritional status and
pulmonary and systemic inflammation in COPD. Hopefully
these will lead to pharmacological and non-pharmacological
advances that will not only improve quality of life but also
prolong it in the face of currently disappointing functional
outcomes from the few available therapeutic approaches.
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